Top MarketRank™ StocksTop MarketRank™NYSE:SYK Stryker (SYK) Stock Price, News & Analysis $331.67 +4.23 (+1.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$325.34▼$334.0750-Day Range$327.45▼$349.6352-Week Range$249.98▼$361.41Volume1.65 million shsAverage Volume1.29 million shsMarket Capitalization$126.35 billionP/E Ratio37.86Dividend Yield0.96%Price Target$372.05 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Stryker alerts: Email Address Stryker MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.79 Rating ScoreUpside/Downside12.2% Upside$372.05 Price TargetShort InterestHealthy1.08% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-0.95Upright™ Environmental ScoreNews Sentiment0.87Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth11.97%From $11.95 to $13.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.98 out of 5 starsMedical Sector3rd out of 936 stocksSurgical & Medical Instruments Industry3rd out of 101 stocks 3.4 Analyst's Opinion Consensus RatingStryker has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageStryker has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stryker's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.08% of the float of Stryker has been sold short.Short Interest Ratio / Days to CoverStryker has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stryker has recently decreased by 6.08%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend YieldStryker has a dividend yield of 0.94%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthStryker has been increasing its dividend for 31 years.Dividend CoverageThe dividend payout ratio of Stryker is 36.53%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Stryker will have a dividend payout ratio of 23.92% next year. This indicates that Stryker will be able to sustain or increase its dividend.Read more about Stryker's dividend. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStryker has received a 60.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Protective clothing", "Synthetic bone grafts", "Surgery simulation software", "Medical laboratory equipment", and "Bone cement" products. See details.Environmental SustainabilityThe Environmental Impact score for Stryker is -0.95. Previous Next 3.3 News and Social Media Coverage News SentimentStryker has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Stryker this week, compared to 11 articles on an average week.Search Interest25 people have searched for SYK on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.MarketBeat Follows17 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stryker insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Stryker is held by insiders.Percentage Held by Institutions77.09% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stryker's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Stryker are expected to grow by 11.97% in the coming year, from $11.95 to $13.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stryker is 37.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Stryker is 37.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 148.37.Price to Earnings Growth RatioStryker has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioStryker has a P/B Ratio of 6.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stryker's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Stryker Stock (NYSE:SYK)Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.Read More SYK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYK Stock News HeadlinesJuly 25 at 6:15 AM | investorplace.com7 American Robotics Stocks to Buy if You're Betting on Trump 2024July 23 at 5:10 PM | marketwatch.comStryker Corp. stock underperforms Tuesday when compared to competitorsJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…July 23 at 3:33 AM | americanbankingnews.comStryker (SYK) Set to Announce Quarterly Earnings on TuesdayJuly 20, 2024 | nz.finance.yahoo.comStryker Corporation (SYK.F)July 16, 2024 | americanbankingnews.comStryker (NYSE:SYK) PT Raised to $372.00July 1, 2024 | globenewswire.comStryker to announce financial results for its second quarter of fiscal year 2024June 18, 2024 | prnewswire.comStryker joins Atrium Health affiliate IRCAD North America to advance surgical training and educationJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…June 17, 2024 | investorplace.com7 Automation Stocks to Propel Your Portfolio to ProfitsJune 4, 2024 | prnewswire.comStryker releases LIFEPAK 35 monitor/defibrillatorJune 3, 2024 | businesswire.comStryker Announces Definitive Agreement to Acquire Artelon, Inc., Offering a Range of Soft Tissue Fixation Solutions for Orthopaedic SurgeonsMay 31, 2024 | seekingalpha.comStryker: Margin Gains Should Drive UpsideMay 29, 2024 | finance.yahoo.comStryker Stock Sees RS Rating Treks Higher To 71May 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024May 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024May 29, 2024 | finance.yahoo.comFirst European Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing SystemMay 29, 2024 | businesswire.comFirst European Surgeries Completed Using Stryker's Gamma4 Hip Fracture Nailing SystemSee More Headlines Receive SYK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 4/30 Dividend3/27/2024Last Earnings4/30/2024Dividend Payable4/30/2024Ex-Dividend for 7/31 Dividend6/28/2024Today7/26/2024Next Earnings (Confirmed)7/30/2024Dividend Payable7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:SYK CUSIP86366710 CIK310764 Webwww.strykercorp.com Phone(269) 385-2600Fax269-385-1062Employees52,000Year Founded1941Price Target and Rating Average Stock Price Target$372.05 High Stock Price Target$406.00 Low Stock Price Target$315.00 Potential Upside/Downside+12.2%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$8.76 Trailing P/E Ratio37.84 Forward P/E Ratio27.74 P/E Growth2.68Net Income$3.17 billion Net Margins16.03% Pretax Margin18.68% Return on Equity23.05% Return on Assets10.88% Debt Debt-to-Equity Ratio0.56 Current Ratio1.71 Quick Ratio0.99 Sales & Book Value Annual Sales$20.50 billion Price / Sales6.16 Cash Flow$13.06 per share Price / Cash Flow25.39 Book Value$48.94 per share Price / Book6.77Miscellaneous Outstanding Shares380,950,000Free Float358,474,000Market Cap$126.29 billion OptionableOptionable Beta0.89 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Kevin A. Lobo (Age 59)Chairman, CEO & President Comp: $5.7MMr. Glenn S. Boehnlein (Age 62)VP & CFO Comp: $2.27MMr. Viju S. Menon (Age 56)Group President of Global Quality & Operations Comp: $1.68MMr. J. Andrew Pierce (Age 50)Group President of MedSurg & Neurotechnology Comp: $2.03MMr. Spencer S. Stiles (Age 47)Group President of Orthopaedics & Spine Comp: $2.02MMr. William E. Berry Jr. (Age 58)VP & Chief Accounting Officer Mr. Robert C. CohenCTO and VP of Global R&D - Joint ReplacementMr. Alan DouvilleVP, Chief Information Officer & Chief Information Security OfficerMr. Jason BeachVice President of Finance & Investor RelationsMr. Robert S. Fletcher (Age 53)VP & Chief Legal Officer Comp: $895.89kMore ExecutivesKey CompetitorsAbbott LaboratoriesNYSE:ABTIntuitive SurgicalNASDAQ:ISRGBoston ScientificNYSE:BSXMedtronicNYSE:MDTBecton, Dickinson and CompanyNYSE:BDXView All CompetitorsInsiders & InstitutionsTFG Advisers LLCSold 90 shares on 7/26/2024Ownership: 0.004%Atlantic Edge Private Wealth Management LLCBought 46 shares on 7/26/2024Ownership: 0.001%Pegasus Asset Management Inc.Sold 42 shares on 7/26/2024Ownership: 0.001%Catalyst Financial Partners LLCBought 70 shares on 7/26/2024Ownership: 0.000%Patriot Financial Group Insurance Agency LLCBought 43 shares on 7/26/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Stryker Stock? SYK Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Stryker Co.: Stryker's stock price is currently trading at $344.72, showing stability and potential for growth in the future. Stryker reported strong earnings results, beating analysts' estimates with an EPS of $2.50 for the quarter. The company has a solid revenue growth rate of 9.7% year-over-year, indicating a healthy financial performance. Stryker has a diverse product portfolio in the medical technology sector, reducing dependency on a single product line. Analysts have set a high target price for Stryker, indicating positive sentiment and potential upside for investors. Cons Investors should be bearish about investing in Stryker Co. for these reasons: Stryker's price-to-earnings ratio of 39.35 is relatively high, suggesting the stock may be overvalued compared to industry peers. The company's debt-to-equity ratio of 0.56 indicates a moderate level of debt, which could pose risks in a challenging economic environment. Stryker's dividend yield of 0.96% may not be attractive to income-focused investors seeking higher dividend returns. The current ratio of 1.71 and quick ratio of 0.99 may raise concerns about the company's liquidity position in the short term. While Stryker has a positive outlook, any adverse regulatory changes or market disruptions could impact its financial performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com. SYK Stock Analysis - Frequently Asked Questions How have SYK shares performed this year? Stryker's stock was trading at $299.46 at the start of the year. Since then, SYK stock has increased by 10.8% and is now trading at $331.67. View the best growth stocks for 2024 here. How were Stryker's earnings last quarter? Stryker Co. (NYSE:SYK) issued its earnings results on Tuesday, April, 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. Read the conference call transcript. What is Kevin A. Lobo's approval rating as Stryker's CEO? 1,492 employees have rated Stryker Chief Executive Officer Kevin A. Lobo on Glassdoor.com. Kevin A. Lobo has an approval rating of 97% among the company's employees. This puts Kevin A. Lobo in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Stryker have any subsidiaries? Stryker subsidiaries include these companies: Vocera Communications, Vocera, Gauss Surgical, OrthoSensor, Wright Medical Group, Cardan Robotics, Mobius Imaging, and more. Who are Stryker's major shareholders? Stryker's top institutional investors include Bank of New York Mellon Corp (1.49%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%) and Raymond James & Associates (0.15%). Insiders that own company stock include Ronda E Stryker, Kevin Lobo, James Andrew Pierce, Allan C Golston, M Kathryn Fink, Viju Menon, Robert S Fletcher, Srikant M Datar, William E Berry Jr and Glenn S Boehnlein. View institutional ownership trends. How do I buy shares of Stryker? Shares of SYK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stryker own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stryker investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Home Depot (HD), Medtronic (MDT), Visa (V), AbbVie (ABBV) and Cisco Systems (CSCO). This page (NYSE:SYK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stryker Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
